HT on Nature journal
Precision medicine is at the heart of the future development of European healthcare. This is the indication of a roadmap presented by LifeTime ,the European consortium which sees HT amongs its associate partners.
The journal Nature published the article “LifeTime and improving European healthcare through cell-based interceptive medicine”. In the article innovators, research pioneers, clinicians, industry leaders and policy makers from all around Europe present a detailed roadmap of how to leverage the latest scientific breakthroughs and technologies over the next decade, to track, understand and treat human cells throughout an individual’s lifetime. A united vision to revolutionise healthcare.
Prof. Giuseppe Testa, Head of Research Centre for Neurogenomics, member of the Lifetime steering committee and co-authore of the report, commented: “LifeTime represents the best of the European spirit, which from frontier research on the cellular basis of human diseases now has the opportunity to gain concrete experience in the lives of patients and in the sustainability of our health systems. The pandemic reminded us of our fragility. Transforming healthcare through a precise understanding of the mechanisms by which a disease begins and develops over time in each patient remains an enormous challenge. But today we are finally beginning to see its feasibility thanks to a new research model that places the clinic at the center of three technological frontiers: organoids, models of each patient’s diseased organs, associated with the ability to analyze them over time, cell by cell, in all their dimensions, also making use of artificial intelligence. We are preparing to choose how to project our country towards rebirth through the Recovery Fund. LifeTime in this sense is a trace of how to do it, in the biomedical field, of how to open the future while remaining anchored to the needs of today that have never before appeared to us with so much drama.”
Share:
You could also like:
-
Colorectal Cancer: ML Enhances Cetuximab Response Predictions
An international collaborative study led by Human Technopole, Candiolo Cancer Institute IRCCS in Turin, the University of Turin, and the Wellcome Sanger Institute in Cambridge (UK) has identified new factors associated with therapeutic response in colorectal cancer. The research has led to the development of a machine-learning model capable of accurately predicting the effects of cetuximab, a drug in clinical use, on different colorectal tumour subtypes. Funded by the AIRC Foundation, the study paves the way to identifying molecular features that could serve as biomarkers for predicting treatment response in patients with this type of cancer.
-
Human Technopole Foundation’s Supplier List online
The Human Technopole Foundation’s Supplier Register is now online.
-
HT Director Zerial Awarded Mercurio Prize for Excellence in Research
The Human Technopole Director, Marino Zerial, has been awarded the 2024 Mercurio Prize in the “Research and Development” category, in recognition of the excellence of his research in the field of cell biology. Zerial, renowned for his studies on the mechanisms of endocytosis and cellular transport, has made significant contributions to the understanding of cellular dynamics, with potential therapeutic applications for diseases such as liver conditions.
-
A new model system for cortical development in vitro
Researchers from Human Technopole, the Institute of Molecular Biotechnology and Bicocca University established a method for developing brain assembloids that allows reproducing salient aspects of the antero-posterior polarity of the human cerebral cortex in vitro and opens new possibilities for disease modelling. The study is published in Nature Methods.
-
The National Facility for Genomics with Clelia Peano
Meet Clelia Peano, Head of the National Facility for Genomics. The Facility offers cutting-edge services to develop robust experimental and analytical workflows to explore different genomic research areas, including DNA and RNA analysis, chromatin structure, and epigenetic mechanisms regulating transcription. The goal is to enhance genomic research in all its aspects, benefiting the entire Italian scientific community.